Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The HOME Trial: Hyperinsulinaemia: the Outcome of Its Metabolic Effects, a Randomized Controlled Trial

This study has been completed.
Sponsor:
Collaborators:
Takeda
LifeScan
Merck KGaA
Dupont Merck
Merck Sharp & Dohme Corp.
Novo Nordisk A/S
Information provided by:
Bethesda General Hospital, Hoogeveen
ClinicalTrials.gov Identifier:
NCT00375388
First received: September 12, 2006
Last updated: NA
Last verified: September 2006
History: No changes posted